search
Back to results

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Primary Purpose

Acne Vulgaris

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
FCD105
3% Minocycline Foam
0.3% Adapalene Foam
Vehicle Foam
Sponsored by
Vyne Therapeutics Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Has facial acne vulgaris with all of the following:

    1. 20 to 50 inflammatory lesions (papules and/or pustules) on the face.
    2. 25 to 100 non-inflammatory lesions (open and closed comedones) on the face.
    3. IGA score of moderate (3) to severe (4).
  2. No more than two active nodules on the face.
  3. Willing to use only the supplied non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study

Exclusion Criteria:

  1. Female who is pregnant or lactating, or is planning a pregnancy during the study.
  2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face that could interfere with the clinical evaluations.
  3. Facial hair (eg, beard, mustache, etc.) that could interfere with the clinical evaluations.
  4. Sunburn on the face.
  5. Severe systemic disease as assessed by the Investigator that might interfere with the conduct of the study or the interpretation of the results.
  6. Subjects who have a documented history of any of the following:

    1. Allergy to tetracycline-class antibiotics or to any ingredient in the study drug.
    2. Pseudomembranous colitis or antibiotic-associated colitis.
    3. Hepatitis or clinically significant liver damage or clinically significant renal impairment.
    4. Known or suspected premalignant or malignant disease (excluding successfully treated skin cancers).
  7. Subjects who have used the following medications:

    Within 1 week prior to randomization:

    • Medicated facial cleansers on the face.
    • Topical acne treatments on the face (other than those listed below).

    Within 4 weeks prior to randomization:

    • Topical retinoids on the face.
    • Topical anti-inflammatories and/or corticosteroids on the face.
    • Topical corticosteroids on body areas other than the face for more than 15 consecutive days and on more than 10% of the body surface area. In body folds, such as axillary and inguinal regions, only mild topical steroids are allowed for short term use (≤15 consecutive days).
    • Systemic antibiotics.
    • Systemic acne treatments.

    Within 12 weeks prior to randomization:

    • Systemic retinoids.
    • Systemic corticosteroids (Note: Intranasal and inhaled corticosteroids may be used throughout the study if the subject is on a stable dose).
  8. Use of sauna during the 2 weeks prior to randomization.
  9. Epilation of the face within 2 weeks prior to randomization.
  10. Folliculitis on the face.
  11. Documented history of depression that is not, in the opinion of the Investigator, currently adequately controlled with medication

Sites / Locations

  • Foamix Institution #134
  • Foamix Institution #121
  • Foamix Institution #106
  • Foamix Institution #103
  • Foamix Institution #122
  • Foamix Institution #109
  • Foamix Institution #132
  • Foamix Institution #107
  • Foamix Institution #127
  • Foamix Institution #135
  • Foamix Institution #101
  • Foamix Institution #118
  • Foamix Institution #120
  • Foamix Institution #128
  • Foamix Institution #130
  • Foamix Institution #116
  • Foamix Institution #123
  • Foamix Institution #126
  • Foamix Institution #124
  • Foamix Institution #136
  • Foamix Institution #114
  • Foamix Institution #111
  • Foamix Institution #102
  • Foamix Institution #115
  • Foamix Institution #108
  • Foamix Institution #104
  • Foamix Institution #133
  • Foamix Institution #125
  • Foamix Institution #119
  • Foamix Institution #110
  • Foamix Institution #117
  • Foamix Institution #112
  • Foamix Institution #105
  • Foamix Institution #131
  • Foamix Institution #113

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

FCD105 Foam

3% Minocycline Foam

0.3% Adapalene Foam

Vehicle Foam

Arm Description

FCD105 Foam

3% Minocycline Foam

0.3% Adapalene Foam

Vehicle Foam

Outcomes

Primary Outcome Measures

Absolute change from Baseline in inflammatory lesion counts at week 12
Statistical superiority of FCD105 vs. vehicle in the absolute change from Baseline in inflammatory lesion counts at Visit 4 (Week12/End of Treatment)
Absolute change from Baseline in non-inflammatory lesion counts at week 12
Statistical superiority of FCD105 vs. vehicle in the absolute change from Baseline in non-inflammatory lesion counts at Visit 4 (Week12/End of Treatment)
Investigator's Global Assessment (IGA) Treatment Success at Week 12
Statistical superiority of FCD105 vs. vehicle in in IGA Treatment Success at Visit 4 (Week 12/End of Treatment), where success is defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from Baseline.

Secondary Outcome Measures

Full Information

First Posted
September 24, 2019
Last Updated
February 2, 2021
Sponsor
Vyne Therapeutics Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04104685
Brief Title
A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.
Official Title
A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study FX2016 40)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
September 18, 2019 (Actual)
Primary Completion Date
February 28, 2020 (Actual)
Study Completion Date
March 3, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vyne Therapeutics Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A study comparing FCD105 to 3% minocycline foam, 0.3% adapalene foam and vehicle foam in patients ≥ 12 years old for the treatment of moderate-to-severe acne.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
446 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FCD105 Foam
Arm Type
Experimental
Arm Description
FCD105 Foam
Arm Title
3% Minocycline Foam
Arm Type
Active Comparator
Arm Description
3% Minocycline Foam
Arm Title
0.3% Adapalene Foam
Arm Type
Active Comparator
Arm Description
0.3% Adapalene Foam
Arm Title
Vehicle Foam
Arm Type
Placebo Comparator
Arm Description
Vehicle Foam
Intervention Type
Combination Product
Intervention Name(s)
FCD105
Intervention Description
Experimental combination
Intervention Type
Drug
Intervention Name(s)
3% Minocycline Foam
Intervention Description
Active Comparator
Intervention Type
Drug
Intervention Name(s)
0.3% Adapalene Foam
Intervention Description
Active Comparator
Intervention Type
Other
Intervention Name(s)
Vehicle Foam
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Absolute change from Baseline in inflammatory lesion counts at week 12
Description
Statistical superiority of FCD105 vs. vehicle in the absolute change from Baseline in inflammatory lesion counts at Visit 4 (Week12/End of Treatment)
Time Frame
12 weeks
Title
Absolute change from Baseline in non-inflammatory lesion counts at week 12
Description
Statistical superiority of FCD105 vs. vehicle in the absolute change from Baseline in non-inflammatory lesion counts at Visit 4 (Week12/End of Treatment)
Time Frame
12 weeks
Title
Investigator's Global Assessment (IGA) Treatment Success at Week 12
Description
Statistical superiority of FCD105 vs. vehicle in in IGA Treatment Success at Visit 4 (Week 12/End of Treatment), where success is defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from Baseline.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has facial acne vulgaris with all of the following: 20 to 50 inflammatory lesions (papules and/or pustules) on the face. 25 to 100 non-inflammatory lesions (open and closed comedones) on the face. IGA score of moderate (3) to severe (4). No more than two active nodules on the face. Willing to use only the supplied non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study Exclusion Criteria: Female who is pregnant or lactating, or is planning a pregnancy during the study. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face that could interfere with the clinical evaluations. Facial hair (eg, beard, mustache, etc.) that could interfere with the clinical evaluations. Sunburn on the face. Severe systemic disease as assessed by the Investigator that might interfere with the conduct of the study or the interpretation of the results. Subjects who have a documented history of any of the following: Allergy to tetracycline-class antibiotics or to any ingredient in the study drug. Pseudomembranous colitis or antibiotic-associated colitis. Hepatitis or clinically significant liver damage or clinically significant renal impairment. Known or suspected premalignant or malignant disease (excluding successfully treated skin cancers). Subjects who have used the following medications: Within 1 week prior to randomization: Medicated facial cleansers on the face. Topical acne treatments on the face (other than those listed below). Within 4 weeks prior to randomization: Topical retinoids on the face. Topical anti-inflammatories and/or corticosteroids on the face. Topical corticosteroids on body areas other than the face for more than 15 consecutive days and on more than 10% of the body surface area. In body folds, such as axillary and inguinal regions, only mild topical steroids are allowed for short term use (≤15 consecutive days). Systemic antibiotics. Systemic acne treatments. Within 12 weeks prior to randomization: Systemic retinoids. Systemic corticosteroids (Note: Intranasal and inhaled corticosteroids may be used throughout the study if the subject is on a stable dose). Use of sauna during the 2 weeks prior to randomization. Epilation of the face within 2 weeks prior to randomization. Folliculitis on the face. Documented history of depression that is not, in the opinion of the Investigator, currently adequately controlled with medication
Facility Information:
Facility Name
Foamix Institution #134
City
Bryant
State/Province
Arkansas
ZIP/Postal Code
72022
Country
United States
Facility Name
Foamix Institution #121
City
Rogers
State/Province
Arkansas
ZIP/Postal Code
72758
Country
United States
Facility Name
Foamix Institution #106
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Facility Name
Foamix Institution #103
City
Fremont
State/Province
California
ZIP/Postal Code
94538
Country
United States
Facility Name
Foamix Institution #122
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
Facility Name
Foamix Institution #109
City
Manhattan Beach
State/Province
California
ZIP/Postal Code
90266
Country
United States
Facility Name
Foamix Institution #132
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Foamix Institution #107
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
Foamix Institution #127
City
Lake City
State/Province
Florida
ZIP/Postal Code
32055
Country
United States
Facility Name
Foamix Institution #135
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33162
Country
United States
Facility Name
Foamix Institution #101
City
Miami
State/Province
Florida
ZIP/Postal Code
33126
Country
United States
Facility Name
Foamix Institution #118
City
Sanford
State/Province
Florida
ZIP/Postal Code
32771
Country
United States
Facility Name
Foamix Institution #120
City
Sunrise
State/Province
Florida
ZIP/Postal Code
33351
Country
United States
Facility Name
Foamix Institution #128
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Facility Name
Foamix Institution #130
City
New Albany
State/Province
Indiana
ZIP/Postal Code
47150
Country
United States
Facility Name
Foamix Institution #116
City
Plainfield
State/Province
Indiana
ZIP/Postal Code
46168
Country
United States
Facility Name
Foamix Institution #123
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40241
Country
United States
Facility Name
Foamix Institution #126
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70809
Country
United States
Facility Name
Foamix Institution #124
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Facility Name
Foamix Institution #136
City
Watertown
State/Province
Massachusetts
ZIP/Postal Code
02472
Country
United States
Facility Name
Foamix Institution #114
City
Clinton Township
State/Province
Michigan
ZIP/Postal Code
48038
Country
United States
Facility Name
Foamix Institution #111
City
Fridley
State/Province
Minnesota
ZIP/Postal Code
55432
Country
United States
Facility Name
Foamix Institution #102
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89148
Country
United States
Facility Name
Foamix Institution #115
City
New York
State/Province
New York
ZIP/Postal Code
10022
Country
United States
Facility Name
Foamix Institution #108
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11790
Country
United States
Facility Name
Foamix Institution #104
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
Facility Name
Foamix Institution #133
City
Gresham
State/Province
Oregon
ZIP/Postal Code
97030
Country
United States
Facility Name
Foamix Institution #125
City
Johnston
State/Province
Rhode Island
ZIP/Postal Code
02919
Country
United States
Facility Name
Foamix Institution #119
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
Facility Name
Foamix Institution #110
City
Arlington
State/Province
Texas
ZIP/Postal Code
76011
Country
United States
Facility Name
Foamix Institution #117
City
College Station
State/Province
Texas
ZIP/Postal Code
77845
Country
United States
Facility Name
Foamix Institution #112
City
Pflugerville
State/Province
Texas
ZIP/Postal Code
78660
Country
United States
Facility Name
Foamix Institution #105
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78213
Country
United States
Facility Name
Foamix Institution #131
City
Layton
State/Province
Utah
ZIP/Postal Code
84041
Country
United States
Facility Name
Foamix Institution #113
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

We'll reach out to this number within 24 hrs